Luca Vigano1,2, Cristiana Soldani1, Barbara Franceschini1, Matteo Cimino1, Ana Lleo2,3, Matteo Donadon1,2, Massimo Roncalli2,4, Alessio Aghemo2,3, Luca Di Tommaso2,4, Guido Torzilli5,6. 1. Department of Surgery, Division of Hepatobiliary & General Surgery, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano - Milan, 20089, Italy. 2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. 3. Division of Internal Medicine and Hepatology, Department of Internal Medicine, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy. 4. Pathology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy. 5. Department of Surgery, Division of Hepatobiliary & General Surgery, Humanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano - Milan, 20089, Italy. guido.torzilli@hunimed.eu. 6. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. guido.torzilli@hunimed.eu.
Abstract
BACKGROUND: Immune infiltrate impacts prognosis of several tumors. To assess the prognostic impact of tumor-infiltrating lymphocytes and macrophages in patients undergoing resection for intrahepatic cholangiocellular carcinoma (ICC). METHODS: All consecutive patients undergoing surgery for ICC between 2008 and 2016 were considered. Inclusion criteria were complete resection and follow-up > 12 months. Tissue sections were immunostained for CD3+, CD4+, CD8+, Foxp3+, and CD68+. The number of positive cells was quantified using a computer-aided image analysis system. Different cut-off values were tested as predictors of overall survival (OS). RESULTS: Fifty-three patients were analyzed. ICC were T1 in 28 patients, multifocal in 11, and N+ in 13. After a median follow-up of 42 months, 5-year OS was 52.1%. The following immune infiltrate values were associated with better OS: CD3+ > 0.10% (5-year OS 63.3% vs. 13.6% if ≤ 0.10%, p = 0.001); CD8+ > 0.10% (56.2% vs. 28.6% if ≤ 0.10%, p = 0.051); Foxp3+ absent (59.4% vs. 16.0% if present, p = 0.049). CD4+ and CD68+ infiltrates were not associated with OS. Three-year OS rates in patients with 0, 1, and ≥ 2 negative prognostic factors were 73.6%, 47.3%, and 14.3%, respectively (p < 0.001). CD3+ infiltrate stratified prognosis in T1 tumors (3-year OS 71.7% if CD3+ > 0.10% vs. 14.3% if ≤ 0.10%, p < 0.001). CONCLUSIONS: Tumor-infiltrating lymphocytes are associated with prognosis of ICC patients after complete surgery. CD3+ and CD8+ infiltrate is associated with higher survival and lower recurrence risk, while Foxp3+ infiltrate is associated with worse prognosis. CD3+ infiltrate allows refining prediction of prognosis in early tumors.
BACKGROUND: Immune infiltrate impacts prognosis of several tumors. To assess the prognostic impact of tumor-infiltrating lymphocytes and macrophages in patients undergoing resection for intrahepatic cholangiocellular carcinoma (ICC). METHODS: All consecutive patients undergoing surgery for ICC between 2008 and 2016 were considered. Inclusion criteria were complete resection and follow-up > 12 months. Tissue sections were immunostained for CD3+, CD4+, CD8+, Foxp3+, and CD68+. The number of positive cells was quantified using a computer-aided image analysis system. Different cut-off values were tested as predictors of overall survival (OS). RESULTS: Fifty-three patients were analyzed. ICC were T1 in 28 patients, multifocal in 11, and N+ in 13. After a median follow-up of 42 months, 5-year OS was 52.1%. The following immune infiltrate values were associated with better OS: CD3+ > 0.10% (5-year OS 63.3% vs. 13.6% if ≤ 0.10%, p = 0.001); CD8+ > 0.10% (56.2% vs. 28.6% if ≤ 0.10%, p = 0.051); Foxp3+ absent (59.4% vs. 16.0% if present, p = 0.049). CD4+ and CD68+ infiltrates were not associated with OS. Three-year OS rates in patients with 0, 1, and ≥ 2 negative prognostic factors were 73.6%, 47.3%, and 14.3%, respectively (p < 0.001). CD3+ infiltrate stratified prognosis in T1 tumors (3-year OS 71.7% if CD3+ > 0.10% vs. 14.3% if ≤ 0.10%, p < 0.001). CONCLUSIONS:Tumor-infiltrating lymphocytes are associated with prognosis of ICC patients after complete surgery. CD3+ and CD8+ infiltrate is associated with higher survival and lower recurrence risk, while Foxp3+ infiltrate is associated with worse prognosis. CD3+ infiltrate allows refining prediction of prognosis in early tumors.
Entities:
Keywords:
Immunology; Intrahepatic cholangiocellular carcinoma; Liver surgery; Prognosis and survival; Staging; Tumor-infiltrating lymphocytes and macrophages
Authors: Olivier Farges; David Fuks; Emmanuel Boleslawski; Yves-Patrice Le Treut; Denis Castaing; Alexis Laurent; Christian Ducerf; Michel Rivoire; Philippe Bachellier; Laurence Chiche; Gennaro Nuzzo; Jean Marc Regimbeau Journal: Ann Surg Date: 2011-11 Impact factor: 12.969
Authors: Kiyohiko Omichi; Jordan M Cloyd; Suguru Yamashita; Ching-Wei D Tzeng; Claudius Conrad; Yun Shin Chun; Thomas A Aloia; Jean-Nicolas Vauthey Journal: Surgery Date: 2017-07-05 Impact factor: 3.982
Authors: Dong Liu; Lara Rosaline Heij; Zoltan Czigany; Edgar Dahl; Sven Arke Lang; Tom Florian Ulmer; Tom Luedde; Ulf Peter Neumann; Jan Bednarsch Journal: J Exp Clin Cancer Res Date: 2022-04-07
Authors: Francesco Fiz; Guido Costa; Nicolò Gennaro; Ludovico la Bella; Alexandra Boichuk; Martina Sollini; Letterio S Politi; Luca Balzarini; Guido Torzilli; Arturo Chiti; Luca Viganò Journal: Diagnostics (Basel) Date: 2021-06-25